These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 32681948)

  • 1. Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.
    Shen AM; Minko T
    J Control Release; 2020 Oct; 326():222-244. PubMed ID: 32681948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled Micro/Nanoparticulate Anticancer Drug Formulations: An Emerging Targeted Drug Delivery Strategy for Lung Cancers.
    Islam N; Richard D
    Curr Cancer Drug Targets; 2019; 19(3):162-178. PubMed ID: 29793407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.
    Okuda T; Okamoto H
    Chem Pharm Bull (Tokyo); 2020; 68(7):589-602. PubMed ID: 32611996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine in pulmonary delivery.
    Mansour HM; Rhee YS; Wu X
    Int J Nanomedicine; 2009; 4():299-319. PubMed ID: 20054434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic Considerations of Inhaled Pharmaceuticals for Systemic Delivery.
    Hu X; Yang FF; Liao YH
    Curr Pharm Des; 2016; 22(17):2532-48. PubMed ID: 26818873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases.
    Yong J; Shu H; Zhang X; Yang K; Luo G; Yu L; Li J; Huang H
    Int J Nanomedicine; 2024; 19():1723-1748. PubMed ID: 38414528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhaled lipid nanocarriers for pulmonary delivery of glucocorticoids: Previous strategies, recent advances and key factors description.
    Altube MJ; Perez N; Romero EL; Morilla MJ; Higa LH; Perez AP
    Int J Pharm; 2023 Jul; 642():123146. PubMed ID: 37330156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Inhaled Formulations and Pulmonary Insulin Delivery Systems.
    Liu H; Shan X; Yu J; Li X; Hu L
    Curr Pharm Biotechnol; 2020; 21(3):180-193. PubMed ID: 31612824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pulmonary delivery of nanoparticle chemotherapy for the treatment of lung cancers: challenges and opportunities.
    Mangal S; Gao W; Li T; Zhou QT
    Acta Pharmacol Sin; 2017 Jun; 38(6):782-797. PubMed ID: 28504252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanotechnology-Assisted Metered-Dose Inhalers (MDIs) for High-Performance Pulmonary Drug Delivery Applications.
    Kumar R; Mehta P; Shankar KR; Rajora MAK; Mishra YK; Mostafavi E; Kaushik A
    Pharm Res; 2022 Nov; 39(11):2831-2855. PubMed ID: 35552983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug delivery and nanoparticles:applications and hazards.
    De Jong WH; Borm PJ
    Int J Nanomedicine; 2008; 3(2):133-49. PubMed ID: 18686775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhalation treatment of lung cancer: the influence of composition, size and shape of nanocarriers on their lung accumulation and retention.
    Garbuzenko OB; Mainelis G; Taratula O; Minko T
    Cancer Biol Med; 2014 Mar; 11(1):44-55. PubMed ID: 24738038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the Route of Administration and PEGylation of Poly(amidoamine) Dendrimers on Their Systemic and Lung Cellular Biodistribution.
    Zhong Q; Merkel OM; Reineke JJ; da Rocha SR
    Mol Pharm; 2016 Jun; 13(6):1866-78. PubMed ID: 27148629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Development of Inhalable Dry Powder Formulations Loaded with Nanoparticles Maintaining Their Original Physical Properties and Functions].
    Okuda T
    Yakugaku Zasshi; 2017; 137(11):1339-1348. PubMed ID: 29093369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Affecting Drug Exposure after Inhalation.
    Nováková A; Šíma M; Slanař O
    Prague Med Rep; 2022; 123(3):129-139. PubMed ID: 36107443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multilayer hollow nanocarrier for pulmonary co-drug delivery of methotrexate and doxorubicin in the form of dry powder inhalation formulation.
    Nozohouri S; Salehi R; Ghanbarzadeh S; Adibkia K; Hamishehkar H
    Mater Sci Eng C Mater Biol Appl; 2019 Jun; 99():752-761. PubMed ID: 30889750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled PYY(3-36) dry-powder formulation for appetite suppression.
    Kuehl PJ; Boyden T; Dobry DE; Doyle-Eisele M; Friesen DT; McDonald JD; Murri BG; Vodak DT; Lyon DK
    Drug Dev Ind Pharm; 2016 Jan; 42(1):150-156. PubMed ID: 26006332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hierarchical pulmonary target nanoparticles via inhaled administration for anticancer drug delivery.
    Chen R; Xu L; Fan Q; Li M; Wang J; Wu L; Li W; Duan J; Chen Z
    Drug Deliv; 2017 Nov; 24(1):1191-1203. PubMed ID: 28844172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pulmonary drug delivery devices and nanosystems as potential treatment strategies for acute respiratory distress syndrome (ARDS).
    Dhege CT; Kumar P; Choonara YE
    Int J Pharm; 2024 May; 657():124182. PubMed ID: 38697584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation strategy and use of excipients in pulmonary drug delivery.
    Pilcer G; Amighi K
    Int J Pharm; 2010 Jun; 392(1-2):1-19. PubMed ID: 20223286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.